Positive results of a phase 2 study support the potential to repurpose intranasal insulin and the SGLT2 inhibitor empagliflozin for Alzheimer’s disease.

Professor Selina Wray and Dr Ashvini Keshavan (UCL Queen Square Institute of Neurology) help examine the decisions of regulatory bodies to use Lecanemab and Donanemab in the NHS.

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Doctors have identified a key warning sign of Alzheimer's disease that could be spotted in the shower - and it's not memory ...

A recent study reveals that a polymer called polyphosphate may stabilize fibrils, protein structures linked to Alzheimer's, Parkinson's, and other neurodegenerative diseases. Researchers used computer ...

Alzheimer’s disease may cause ... but early diagnosis and treatment may help improve cognitive function and quality of life, as well as slow down disease progression. Some ways to help slow ...

A finger-prick blood test can accurately identify p-tau217 — a key biomarker of Alzheimer's disease (AD) — without the need ...

Health system changes that bolster access to disease-modifying treatments for Alzheimer’s disease could reduce the disparities in diagnosis and improve health equity in disease treatment overall, ...

Researchers from The Florey Institute have evaluated a new diagnostic blood test for Alzheimer's disease, demonstrating its ...

It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer’s disease, and Parkinson’s disease. The company was founded by Asa ...

The award-winning image highlights the intricate details of two kinds of cells: a rounder, less specialized kind and longer, ...

The medical community remains committed to improving treatment for those living with Alzheimer’s and other forms of dementia.